Clinical trials: Subcutaneous Tumors
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa [MK-3475A] administered subcutaneously (SC) over pembrolizumab [MK-3475]…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT06099782
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
- Where
- 45 sites in United States, Argentina and 8 more
- Volunteers
- 147 people
- Sponsor
- Merck Sharp & Dohme LLC
Early Breast Cancer
A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)
This study involves a two-part design. Part 1 is designed to determine the optimal dose of subcutaneous (SC) Perjeta, injected alone or mixed with Herceptin, that results in comparable exposure to intravenous (IV) Perjeta.
- Trial name
- NCT02738970
- Testing
- Trastuzumab, Pertuzumab
- Where
- 2 sites in New Zealand
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
FIGO Stage III and IV Ovarian Cancer, FIGO Stage III and IV Fallopian Tube Cancer
IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer
This is a single center, randomized phase II study of an IL-15Rα-Fc super-agonist complex (ALT-803) given as maintenance therapy after the completion of 1st line IV/IP chemotherapy for the treatment of advanced ovarian, fallopian…
- Conditions
- FIGO Stage III and IV Ovarian Cancer, FIGO Stage III and IV Fallopian Tube Cancer, FIGO Stage III Primary Peritoneal Cancer
- Trial name
- NCT03054909
- Testing
- ALT-803 Subcutaneous, ALT-803 Intraperitoneal
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Severe Caner Pain
A Study to Assess the Safety and Tolerability of Oxycodone Hydrochloride 50mg/mL Administered as an Infusion
Assessing the safety and tolerability of Oxycodone Hydrochloride 50mg/mL in subjects with severe cancer pain.
- Trial name
- NCT00626600
- Testing
- Oxycodone Hydrochloride
- Where
- United Kingdom
- Volunteers
- 33 people
- Sponsor
- Mundipharma Research Limited
Myelodysplastic Syndromes
Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)
The primary purpose of this study is to determine the effectiveness and safety of azacitidine in the treatment of Taiwanese subjects with higher-risk Myelodysplastic Syndrome (MDS).
- Trial name
- NCT01201811
- Testing
- Azacitidine
- Where
- 11 sites in Taiwan
- Volunteers
- 44 people
- Sponsor
- Celgene
Breast Cancer
A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
This open-label, multicenter, Phase IIIb study will assess the safety, tolerability and efficacy of a combination therapy of intravenous (IV) pertuzumab (Perjeta), trastuzumab (Herceptin) SC, and taxane chemotherapy (docetaxel…
- Trial name
- SAPPHIRE (NCT02019277)
- Testing
- Docetaxel, Nab-paclitaxel, Paclitaxel
- Where
- 13 sites in Australia
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Neoplasms, Pain
The Pain Pen for Breakthrough Cancer Pain
The purpose of this study is to see whether injection of hydromorphone through a subcutaneous injection device is more effective in treating breakthrough cancer pain than oral morphine.
- Trial name
- NCT00125801
- Testing
- Subcutaneous hydromorphone delivered by pain pen
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Erasmus Medical Center
Chemotherapy, Anemia
Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy
The purpose of this study was to compare the effectiveness of epoetin alfa treatment on hemoglobin (Hb) response, quality of life (QoL), health care resource utilization and patient productivity when epoetin alfa was administered…
- Conditions
- Chemotherapy, Anemia, Cancer
- Trial name
- NCT00524407
- Testing
- Epoetin alfa
- Volunteers
- 273 people
- Sponsor
- Ortho Biotech, Inc.
Urinary Tract Infections
Ertapenem Administered Subcutaneously Versus Intravenously
Infections requiring intravenous antimicrobial therapy are very common events in patients with advanced cancer. Nevertheless, these patients frequently present vascular damages becoming extremely difficult to access and maintain…
- Trial name
- NCT03218800
- Testing
- Ertapenem
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Kidney Cancer
Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Biological therapies, such as interleukin-2 and interferon, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00416871
- Testing
- aldesleukin, recombinant interferon alfa
- Volunteers
- 220 people
- Sponsor
- Centre Leon Berard
MDS, AML
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function
The purpose of this study is to evaluate three things. The first being whether azacitidine is absorbed in the body at the same rate or proportion for different concentrations.
- Conditions
- MDS, AML, Solid Tumors, Multiple Myeloma
- Trial name
- RENAL (NCT00652626)
- Testing
- azacitidine
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- Celgene
Breast Cancer
To Evaluate the Effectiveness and Safety of Single-port Robotic-assisted Subcutaneous Gland Resection Combined With Immediate Breast Reconstruction in Breast Cancer
The new technology of robotic surgery system, as an emerging technology, has shown certain application prospects in breast surgery.
- Trial name
- NCT06706726
- Testing
- sentinel lymph node biopsy, Single-port robotic-assisted axillary lymph node dissection
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Leukemia
Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation
The goal of this clinical research study is to learn if bortezomib can help to control MDS. The safety of this drug will also be studied. Bortezomib is designed to block a protein that causes cells to grow.
- Trial name
- NCT01891968
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
The trial aims to demonstrate the non-inferiority of subcutaneous to intravenous isatuximab administration in transplant-eligible patients with newly diagnosed multiple myeloma.
- Trial name
- NCT05804032
- Testing
- Isatuximab, Lenalidomide, Bortezomib
- Where
- 91 sites in Austria, Germany
- Volunteers
- 514 people
- Sponsor
- University of Heidelberg Medical Center
Melanoma
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration.
- Trial name
- NCT06101134
- Testing
- relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab
- Where
- 31 sites in United States, Chile and 3 more
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of…
- Conditions
- Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma
- Trial name
- NCT03598998
- Testing
- Pembrolizumab, Pralatrexate
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- City of Hope Medical Center
Cancer Pain, Erector Spinae Plane Block
Intermittent Erector Spinae Plane Block Via Subcutaneous Port for Cancer Pain
Cancer-related pain is a common and challenging problem in patients with lung cancer, often requiring long-term pain management.
- Trial name
- NCT07396558
- Testing
- Erector Spinae Plane Block
- Where
- Vietnam
- Volunteers
- 180 people
- Sponsor
- Hanoi Medical University
Moderate or Severe Submental Fullness
Patient Experience Study of Deoxycholic Acid Injection
The objectives of this study are to determine the safety of deoxycholic acid subcutaneous (SC) injections in the submental area and to evaluate the effects of four interventions, relative to placebo in the submental area…
- Trial name
- NCT02007434
- Testing
- Deoxycholic Acid Injection, Cold Compress, Lidocaine / Epinephrine
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Kythera Biopharmaceuticals
Melanoma (Skin)
Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Interleukin-7 may stimulate a person's white blood cells to kill tumor cells. Vaccines made from peptides may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00091338
- Testing
- MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Gastric/Gastroesophageal Junction Cancer, Breast Cancer
A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
This is an open-label, multicenter, Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of KJ015 administered subcutaneously in participants with HER2-expressing solid tumors.
- Conditions
- Gastric/Gastroesophageal Junction Cancer, Breast Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT07036185
- Testing
- KJ015 Injection (Subcutaneous Injection)
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.